Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
radiopharmaceuticals
Biotech
Telix shows 'promising’ 13-month OS in ph. 2 brain cancer study
Telix Pharmaceuticals has pointed to “promising efficacy” for its radiation therapy in a small study of patients with brain cancer.
James Waldron
Apr 16, 2025 6:30am
ADCs to cell therapy: How AZ aims to 'redefine' oncology
Apr 9, 2025 11:44am
ITM shares details of radiotherapy's ph. 3 win, reveals OS miss
Mar 6, 2025 4:30am
Lilly inks AdvanCell, OliX deals to expand in radiopharma, MASH
Feb 10, 2025 9:40am
Sanofi-backed radiopharma AdvanCell secures $112M series C
Feb 3, 2025 9:00am
Radioisotope manufacturer ITM grabs spotlight with phase 3 win
Jan 28, 2025 5:00am
